US 11090344
Adenovirus and immunomodulator combination therapy
granted A61KA61K35/761A61K39/39541
Quick answer
US patent 11090344 (Adenovirus and immunomodulator combination therapy) held by The Board of Regents of the University of Texas System expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K35/761, A61K39/39541, A61K9/0019, A61P